Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Shannon Kenney

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Anatomy

Physiology

Disorders

Concepts & Ideas

Molecular Sequence Data

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
24
Holley-Guthrie, Elizabeth
11
Feng, Wen-hai
10
Mauser, Amy
9
Delecluse, Henri-Jacques
8
Pagano, Joseph
6
Bhende, Prasanna
6
Seaman, William
5
Hong, Gregory
5
Israel, Bruce
5
Westphal, Eva
4
Adamson, AL
4
Dickerson, Sarah
4
Morrison, Thomas
4
Gulley, Margaret
4
Markovitz, David

Sign-in to see all Coauthors

Publications

TOP 3
Feng Wen-hai; Kraus Richard J; Dickerson Sarah J; Lim Hui Jun; Jones Richard J; Yu Xianming; Mertz Janet E; Kenney Shannon C
ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells.
Jones Richard J; Seaman William T; Feng Wen-Hei; Barlow Elizabeth; Dickerson Sarah; Delecluse Henri-Jacque; Kenney Shannon C
Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease.
Bhende Prasanna M; Dickerson Sarah J; Sun Xiaoping; Feng Wen-Hai; Kenney Shannon C
X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Shannon Kenney (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2007: Feng Wen-hai; Kraus Richard J; Dickerson Sarah J; Lim Hui Jun; Jones Richard J; Yu Xianming; Mertz Janet E; Kenney Shannon C
ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells.
Journal of virology 2007;81(18):10113-22.
2007: Jones Richard J; Seaman William T; Feng Wen-Hei; Barlow Elizabeth; Dickerson Sarah; Delecluse Henri-Jacque; Kenney Shannon C
Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease.
International journal of cancer. Journal international du cancer 2007;121(6):1274-81.
2007: Bhende Prasanna M; Dickerson Sarah J; Sun Xiaoping; Feng Wen-Hai; Kenney Shannon C
X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D.
Journal of virology 2007;81(14):7363-70.
2007: Jones Richard J; Dickerson Sarah; Bhende Prassana M; Delecluse Henri-Jacque; Kenney Shannon C
Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9.
The Journal of biological chemistry 2007;282(11):8317-24.
2006: Feng Wen-Hai; Kenney Shannon C
Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression.
Cancer research 2006;66(17):8762-9.
2006: González Carlos M; Wong Emily L; Bowser Brian S; Hong Gregory K; Kenney Shannon; Damania Blossom
Identification and characterization of the Orf49 protein of Kaposi's sarcoma-associated herpesvirus.
Journal of virology 2006;80(6):3062-70.
2006: Kenney Shannon
Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.
Transactions of the American Clinical and Climatological Association 2006;117():55-73; discussion 73-4.
2005: Israel Bruce F; Gulley Margaret; Elmore Sandra; Ferrini Silvano; Feng Wen-hai; Kenney Shannon C
Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas.
Molecular cancer therapeutics 2005;4(12):2037-44.
2005: Hong Gregory K; Gulley Margaret L; Feng Wen-Hai; Delecluse Henri-Jacques; Holley-Guthrie Elizabeth; Kenney Shannon C
Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.
Journal of virology 2005;79(22):13993-4003.
2005: Hong Gregory K; Kumar Pawan; Wang Ling; Damania Blossom; Gulley Margaret L; Delecluse Henri-Jacques; Polverini Peter J; Kenney Shannon C
Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.
Journal of virology 2005;79(22):13984-92.
2005: Bhende Prasanna M; Seaman William T; Delecluse Henri-Jacques; Kenney Shannon C
BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186.
Journal of virology 2005;79(12):7338-48.
2005: Holley-Guthrie Elizabeth A; Seaman William T; Bhende Prasanna; Merchant Juanita L; Kenney Shannon C
The Epstein-Barr virus protein BMRF1 activates gastrin transcription.
Journal of virology 2005;79(2):745-55.
2004: Feng Wen-hai; Cohen Jeffrey I; Fischer Steven; Li Li; Sneller Michael; Goldbach-Mansky Raphael; Raab-Traub Nancy; Delecluse Henri-Jacques; Kenney Shannon C
Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.
Journal of the National Cancer Institute 2004;96(22):1691-702.
2004: Li Yuling; Mahajan Nupam P; Webster-Cyriaque Jennifer; Bhende Prasanna; Hong Gregory K; Earp H Shelton; Kenney Shannon
The C-mer gene is induced by Epstein-Barr virus immediate-early protein BRLF1.
Journal of virology 2004;78(21):11778-85.
2004: Morrison Thomas E; Kenney Shannon C
BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function.
Virology 2004;328(2):219-32.
2004: Bhende Prasanna M; Seaman William T; Delecluse Henri-Jacques; Kenney Shannon C
The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome.
Nature genetics 2004;36(10):1099-104.
2004: Makhov Alexander M; Subramanian Deepa; Holley-Guthrie Elizabeth; Kenney Shannon C; Griffith Jack D
The Epstein-Barr virus polymerase accessory factor BMRF1 adopts a ring-shaped structure as visualized by electron microscopy.
The Journal of biological chemistry 2004;279(39):40358-61.
2004: Hong Gregory K; Delecluse Henri-Jacques; Gruffat Henri; Morrison Thomas E; Feng Wen-Hai; Sergeant Alain; Kenney Shannon C
The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1.
Journal of virology 2004;78(10):4983-92.
2004: Li Yuling; Webster-Cyriaque Jennifer; Tomlinson Christine C; Yohe Marielle; Kenney Shannon
Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression.
Journal of virology 2004;78(8):4197-206.
2004: Feng Wen-hai; Hong Gregory; Delecluse Henri-Jacques; Kenney Shannon C
Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Journal of virology 2004;78(4):1893-902.
2004: Morrison Thomas E; Mauser Amy; Klingelhutz Aloysius; Kenney Shannon C
Epstein-Barr virus immediate-early protein BZLF1 inhibits tumor necrosis factor alpha-induced signaling and apoptosis by downregulating tumor necrosis factor receptor 1.
Journal of virology 2004;78(1):544-9.
2003: Israel Bruce F; Kenney Shannon C
Virally targeted therapies for EBV-associated malignancies.
Oncogene 2003;22(33):5122-30.
2002: Mauser Amy; Holley-Guthrie Elizabeth; Zanation Adam; Yarborough Wendall; Kaufmann William; Klingelhutz Aloysius; Seaman William T; Kenney Shannon
The Epstein-Barr virus immediate-early protein BZLF1 induces expression of E2F-1 and other proteins involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells.
Journal of virology 2002;76(24):12543-52.
2002: Mauser Amy; Saito Shin'ichi; Appella Ettore; Anderson Carl W; Seaman William T; Kenney Shannon
The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms.
Journal of virology 2002;76(24):12503-12.
2002: Feng Wen-hai; Westphal Eva; Mauser Amy; Raab-Traub Nancy; Gulley Margaret L; Busson Pierre; Kenney Shannon C
Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.
Journal of virology 2002;76(21):10951-9.
2002: Mauser Amy; Holley-Guthrie Elizabeth; Simpson Dennis; Kaufmann William; Kenney Shannon
The Epstein-Barr virus immediate-early protein BZLF1 induces both a G(2) and a mitotic block.
Journal of virology 2002;76(19):10030-7.
2002: Feng Wen-hai; Israel Bruce; Raab-Traub Nancy; Busson Pierre; Kenney Shannon C
Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.
Cancer research 2002;62(6):1920-6.
2001: Morrison T E; Mauser A; Wong A; Ting J P; Kenney S C
Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein.
Immunity 2001;15(5):787-99.
2001: Swenson J J; Holley-Guthrie E; Kenney S C
Epstein-Barr virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation.
Journal of virology 2001;75(13):6228-34.
2001: Darr C D; Mauser A; Kenney S
Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.
Journal of virology 2001;75(13):6135-42.
2001: Israel B F; Pickles R J; Segal D M; Gerard R D; Kenney S C
Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody.
Journal of virology 2001;75(11):5215-21.
2001: Adamson A L; Kenney S
Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.
Journal of virology 2001;75(5):2388-99.
2000: Westphal E M; Blackstock W; Feng W; Israel B; Kenney S C
Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Cancer research 2000;60(20):5781-8.
2000: Adamson A L; Darr D; Holley-Guthrie E; Johnson R A; Mauser A; Swenson J; Kenney S
Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases.
Journal of virology 2000;74(3):1224-33.
2000: Westphal E M; Ge J; Catchpole J R; Ford M; Kenney S C
The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo.
Cancer gene therapy 2000;7(1):97-106.
1999: Adamson A L; Kenney S
The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein.
Journal of virology 1999;73(8):6551-8.
1999: Swenson J J; Mauser A E; Kaufmann W K; Kenney S C
The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction.
Journal of virology 1999;73(8):6540-50.
1999: Westphal E M; Mauser A; Swenson J; Davis M G; Talarico C L; Kenney S C
Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Cancer research 1999;59(7):1485-91.
1999: Zhang Q; Holley-Guthrie E; Dorsky D; Kenney S
Identification of transactivator and nuclear localization domains in the Epstein-Barr virus DNA polymerase accessory protein, BMRF1.
The Journal of general virology 1999;80 ( Pt 1)():69-74.
1998: Adamson A L; Kenney S C
Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product.
Virology 1998;251(1):187-97.
1998: Kenney S; Ge J Q; Westphal E M; Olsen J
Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors.
Human gene therapy 1998;9(8):1131-41.
1997: Zalani S; Coppage A; Holley-Guthrie E; Kenney S
The cellular YY1 transcription factor binds a cis-acting, negatively regulating element in the Epstein-Barr virus BRLF1 promoter.
Journal of virology 1997;71(4):3268-74.
1997: Zhang Q; Holley-Guthrie E; Ge J Q; Dorsky D; Kenney S
The Epstein-Barr virus (EBV) DNA polymerase accessory protein, BMRF1, activates the essential downstream component of the EBV oriLyt.
Virology 1997;230(1):22-34.
1997: Hong Y; Holley-Guthrie E; Kenney S
The bZip dimerization domain of the Epstein-Barr virus BZLF1 (Z) protein mediates lymphoid-specific negative regulation.
Virology 1997;229(1):36-48.
1996: Rogers R P; Ge J Q; Holley-Guthrie E; Hoganson D K; Comstock K E; Olsen J C; Kenney S
Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase.
Human gene therapy 1996;7(18):2235-45.
1996: Zalani S; Holley-Guthrie E; Kenney S
Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(17):9194-9.
1996: Zhang Q; Hong Y; Dorsky D; Holley-Guthrie E; Zalani S; Elshiekh N A; Kiehl A; Le T; Kenney S
Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication.
Journal of virology 1996;70(8):5131-42.
1995: Zalani S; Holley-Guthrie E; Kenney S
The Zif268 cellular transcription factor activates expression of the Epstein-Barr virus immediate-early BRLF1 promoter.
Journal of virology 1995;69(6):3816-23.
1994: Gutsch D E; Marcu K B; Kenney S C
The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters.
Cellular and molecular biology (Noisy-le-Grand, France) 1994;40(6):747-60.
1994: Gutsch D E; Holley-Guthrie E A; Zhang Q; Stein B; Blanar M A; Baldwin A S; Kenney S C
The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B.
Molecular and cellular biology 1994;14(3):1939-48.
1994: Zhang Q; Gutsch D; Kenney S
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency.
Molecular and cellular biology 1994;14(3):1929-38.
1994: Furnari F B; Zacny V; Quinlivan E B; Kenney S; Pagano J S
RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism.
Journal of virology 1994;68(3):1827-36.
1993: Quinlivan E B; Holley-Guthrie E A; Norris M; Gutsch D; Bachenheimer S L; Kenney S C
Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1.
Nucleic acids research 1993;21(14):1999-2007.
1992: Zalani S; Holley-Guthrie E A; Gutsch D E; Kenney S C
The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor.
Journal of virology 1992;66(12):7282-92.
1992: Quinlivan E B; Norris M; Bouldin T W; Suzuki K; Meeker R; Smith M S; Hall C; Kenney S
Subclinical central nervous system infection with JC virus in patients with AIDS.
The Journal of infectious diseases 1992;166(1):80-5.
1992: Kenney S C; Holley-Guthrie E; Quinlivan E B; Gutsch D; Zhang Q; Bender T; Giot J F; Sergeant A
The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells.
Molecular and cellular biology 1992;12(1):136-46.
1991: Sung N S; Kenney S; Gutsch D; Pagano J S
EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus.
Journal of virology 1991;65(5):2164-9.
1990: Holley-Guthrie E A; Quinlivan E B; Mar E C; Kenney S
The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner.
Journal of virology 1990;64(8):3753-9.
1990: Quinlivan E B; Holley-Guthrie E; Mar E C; Smith M S; Kenney S
The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent.
Journal of virology 1990;64(4):1817-20.
1989: Markovitz D M; Kenney S; Kamine J; Smith M S; Davis M; Huang E S; Rosen C; Pagano J S
Disparate effects of two herpesvirus [corrected] immediate-early gene trans-activators on the HIV-1 LTR.
Virology 1989;173(2):750-4.
1989: Kenney S; Holley-Guthrie E; Mar E C; Smith M
The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators.
Journal of virology 1989;63(9):3878-83.
1989: Kenney S; Kamine J; Holley-Guthrie E; Mar E C; Lin J C; Markovitz D; Pagano J
The Epstein-Barr virus immediate-early gene product, BMLF1, acts in trans by a posttranscriptional mechanism which is reporter gene dependent.
Journal of virology 1989;63(9):3870-7.
1989: Kenney S; Kamine J; Holley-Guthrie E; Lin J C; Mar E C; Pagano J
The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters.
Journal of virology 1989;63(4):1729-36.
1988: Pagano J S; Kenney S; Markovitz D; Kamine J
Epstein-Barr virus and interactions with human retroviruses.
Journal of virological methods 1988;21(1-4):229-39.
1988: Kenney S; Kamine J; Markovitz D; Fenrick R; Pagano J
An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(5):1652-6.
1987: Davis M G; Kenney S C; Kamine J; Pagano J S; Huang E S
Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(23):8642-6.

Sign-in to see more